Big Pharmas May Turn to Dealmaking to Re-stock Drug Pipelines -- Market Talk

DOW JONES & COMPANY, INC. 8:44 AM ET 12/1/2015




Symbol

Last

Price Change


LLY 84.43down +2.39 (+2.91%)
JNJ 101.73down +0.49 (+0.48%)
QUOTES AS OF 10:00:29 AM ET 12/01/2015


9:44 ET - Eli Lilly(LLY) , Merck (MRK) and Johnson & Johnson(JNJ) could be in the hunt for deals that bolster their drug pipelines, Barclays says. Such R&D-based deals would add more value than many recent transactions that have focused on cutting costs, Barclays says. Lilly might want to bolster its early- and mid-stage pipeline, while Johnson & Johnson(JNJ) might look for compounds in rare diseases and cancer and Merck could also eye cancer, Barclays says. Pfizer (PFE) may also look for new drugs to cushion against patent expiries for several drugs, Barclays says. (jonathan.rockoff@wsj.com; @jonathanrockoff)

(END) Dow Jones Newswires 12-01-150944ET Copyright (c) 2015 Dow Jones & Company, Inc.